Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $114.58, for a total transaction of $2,172,436.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Larry L. Wood also recently made the following trade(s):

  • On Wednesday, November 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The stock was sold at an average price of $104.76, for a total transaction of $1,986,249.60.

Edwards Lifesciences Corporation (NYSE EW) traded down $0.09 during trading on Friday, reaching $114.22. 2,464,707 shares of the company were exchanged, compared to its average volume of 1,647,669. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The company has a market cap of $24,420.94, a price-to-earnings ratio of 31.97, a PEG ratio of 2.06 and a beta of 0.51. Edwards Lifesciences Corporation has a twelve month low of $86.55 and a twelve month high of $121.45.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The firm had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The business’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS. research analysts anticipate that Edwards Lifesciences Corporation will post 3.76 earnings per share for the current year.

Edwards Lifesciences announced that its board has authorized a share buyback program on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Institutional investors have recently bought and sold shares of the stock. Alps Advisors Inc. grew its stake in Edwards Lifesciences by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after buying an additional 14 shares in the last quarter. Veritable L.P. boosted its stake in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock valued at $738,000 after purchasing an additional 71 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in shares of Edwards Lifesciences by 2.8% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 2,776 shares of the medical research company’s stock valued at $320,000 after purchasing an additional 76 shares in the last quarter. Stephens Inc. AR boosted its stake in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Stephens Inc. AR now owns 7,831 shares of the medical research company’s stock valued at $926,000 after purchasing an additional 91 shares in the last quarter. Finally, Johnson Financial Group Inc. boosted its stake in shares of Edwards Lifesciences by 7.1% in the 2nd quarter. Johnson Financial Group Inc. now owns 1,639 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 109 shares in the last quarter. 81.82% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have commented on the stock. Morgan Stanley lowered their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research report on Thursday, October 26th. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 1st. Canaccord Genuity reaffirmed a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a research report on Sunday, October 8th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $120.00 price objective on shares of Edwards Lifesciences in a research report on Saturday, September 30th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences presently has an average rating of “Buy” and an average price target of $126.43.

ILLEGAL ACTIVITY WARNING: “Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/15/larry-l-wood-sells-18960-shares-of-edwards-lifesciences-corporation-ew-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.